Foghorn Therapeutics Inc.
FHTX
$6.26
-$0.23-3.54%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 391.95% | -64.67% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 391.95% | -64.67% | |||
| Cost of Revenue | 1.45% | -17.18% | |||
| Gross Profit | 83.65% | -17.13% | |||
| SG&A Expenses | -3.45% | -3.18% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.15% | -13.88% | |||
| Operating Income | 59.19% | -10.09% | |||
| Income Before Tax | 63.82% | 8.26% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 63.82% | 8.26% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 63.82% | 8.26% | |||
| EBIT | 59.19% | -10.09% | |||
| EBITDA | 59.81% | -13.52% | |||
| EPS Basic | 64.38% | 16.80% | |||
| Normalized Basic EPS | 64.39% | -3.66% | |||
| EPS Diluted | 64.38% | 16.80% | |||
| Normalized Diluted EPS | 64.39% | -3.66% | |||
| Average Basic Shares Outstanding | 1.57% | 10.27% | |||
| Average Diluted Shares Outstanding | 1.57% | 10.27% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||